The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection

Simple item page
dc.contributor.authorFigueroa, MI
dc.contributor.authorCamiro-Zuñiga, A
dc.contributor.authorBelaunzaran-Zamudio, PF
dc.contributor.authorSierra Madero, J
dc.contributor.authorAndrade Villanueva, J
dc.contributor.authorArribas, JR
dc.contributor.authorLama, JR
dc.contributor.authorCecchini, DM
dc.contributor.authorLopardo, G
dc.contributor.authorCrabtree-Ramírez, B
dc.contributor.authorGun, Ana
dc.contributor.authorPatterson, Patricia
dc.contributor.authorVI, Fink
dc.contributor.authorSued, Omar
dc.contributor.authorCahn, Pedro
dc.date.accessioned2024-05-23T23:49:23Z
dc.date.available2024-05-23T23:49:23Z
dc.date.issued2020-12-17
dc.descriptionFil: Gun A. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Sued O. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractObjectives To assess the effect of protease inhibitor (PI)-based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)-naïve patients using data from randomized controlled clinical trials. Methods We pooled data from the GARDEL and ANDES studies, both randomized controlled clinical trials that recruited ART-naïve people living with HIV and randomly assigned them to receive PI-based dual therapy (DT) or triple therapy (TT) aiming to compare viral efficacy. We compared median CD4/CD8 ratios and the proportion of patients with CD4/CD8 ratio > 1 at 48 weeks after ART initiation in both treatment arms using the Mann–Whitney U-test and the χ2 test. We performed subgroup analysis for patients > 50 years old, with baseline CD4 counts ≤ 200 cells/μL, viral load > 100 000 HIV RNA copies/mL, and ritonavir-boosted lopinavir-based therapy. Results We analysed data from 571 patients: 292 on DT and 279 on TT. No differences were observed in CD4/CD8 ratio (0.632 vs. 0.617, P = 0.729) or in the proportion of patients with CD4/CD8 ratio > 1 (17.9% vs. 19.3%, P = 0.678) 48 weeks after ART initiation. Subgroup analysis showed no further differences. Conclusion The impact of PI-based DT regimens on the CD4/CD8 ratio during the first year of treatment for ART-naïve patients is similar to that of TT.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1111/hiv.13008
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1349
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesHIV Medicine;2021 Apr; 22(4): 254-261
dc.rightsopenAccesses_ES
dc.subjectCD4-CD8 Ratioes_ES
dc.subjectDarunavires_ES
dc.subjectLamivudinees_ES
dc.subjectLopinavires_ES
dc.titleThe effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infectiones_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
HIV Medicine - 2020 - Figueroa - The effect of protease inhibitor‐based dual antiretroviral regimens on CD4 CD8 ratio.pdf
Size:
228.57 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos